The use of long-acting antiretroviral regimens will not be suitable for all people living with HIV for various reasons (previous virological failure with drugs of the same class, side effects, logistic difficulties, and costs). We think that short-cycle therapies could represent a feasible and valuable option for antiretroviral treatment optimization in selected individuals. So here we review clinical evidence about efficacy of short-cycle therapy in suppressed HIV-infected patients.
Get full access to this article
View all access options for this article.
References
1.
CohenCJ, ColsonAE, Sheble-HallAG, et al.Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials, 2007; 8(1):19–23; doi: 10.1310/hct0801-19
2.
BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): A randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV, 2016; 3(9):e421–e430; doi: 10.1016/S2352-3018(16)30054-6
3.
TurkovaA, MooreCL, ButlerK, et al., BREATHER (PENTA 16) trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. PLoS One, 2018; 13(4):e0196239; doi: 10.1371/journal.pone.0196239
4.
BernaysS, PapariniS, SeeleyJ, et al.Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): Is it acceptable to young people living with HIV?. BMJ Open, 2017; 7(2):e012934; doi: 10.1136/bmjopen-2016-012934
5.
TierrablancaLE, OchalekJ, FordD, et al.BREATHER (PENTA 16) Trial Group. Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries. Medicine (Baltimore), 2018; 97(7):e9698. Erratum in: Medicine (Baltimore) (2018) 97:e0012; doi: 10.1097/MD.0000000000009698
6.
LeibowitchJ, MathezD, de TruchisP, et al.Short cycles of antiretroviral drugs provide intermittent yet effective therapy: A pilot study in 48 patients with chronic HIV infection. FASEB J, 2010; 24(6):1649–1655; doi.org/10.1096/fj.09-148676
7.
LeibowitchJ, MathezD, de TruchisP, et al.Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: The ICCARRE project. FASEB J, 2015; 29(6):2223–2234; doi.org/10.1096/fj.14-260315
8.
RudyBJ, SleasmanJ, KapogiannisB, et al; Adolescent Trials Network for HIV/AIDS Interventions. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: The impact on viral load suppression. AIDS Res Hum Retroviruses, 2009; 25(6):555–561; doi: 10.1089/aid.2008.0203
9.
de TruchisP, AssoumouL, LandmanR, et al; ANRS 162-4D Study Group. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: The ANRS 162-4D trial. J Antimicrob Chemother, 2018; 73(3):738–747; doi: 10.1093/jac/dkx434
10.
CalinR, LandowskiS, ValantinMA, et al.Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients. J Antimicrob Chemother, 2020; 75(5):1321–1323; doi: 10.1093/jac/dkz555
11.
LanzafameM, LattuadaE, GottardoR, et al.Short-cycle therapy (5days on/2days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection. Int J Antimicrob Agents, 2021; 57(3):106290; doi: 10.1016/j.ijantimicag.2021.106290
12.
LuiseD, LattuadaE, RizzardoS, et al.Short-cycle therapy in HIV-infected adults: Rilpivirine combination 4days on/3days off therapy. J Antimicrob Chemother, 2022; 77(3):747–752; doi: 10.1093/jac/dkab442
13.
LandmanR, de TruchisP, AssoumouL, et al.ANRS 170 QUATUOR study group. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): A randomised, open-label, multicentre, parallel, non-inferiority trial. Lancet HIV, 2022; 9(2):e79–e90; doi: 10.1016/S2352-3018(21)00300-3
14.
LandmanR, De TruchisP, AssoumouL, et al.ANRS 170 QUATUOR study group. ANRS 170 QUATUOR 4/7days maintenance strategy in antiretroviral treated adults with HIV-1 infection: An open randomised parallel non-inferiority phase III trial. In: International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Mexico City July 21–24.2019. Abstract 4817.
15.
BoulasselM-R, ChomontN, PaiNP, et al.CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol, 2012; 53(1):29–32; doi: 10.1016/j.jcv.2011.09.018
16.
LiJZ, EtemadB, AhmedH, et al.The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS, 2016; 30(3):343–353; doi: 10.1097/QAD.0000000000000953
17.
SellemB, AbdiB, LêM, et al.Intermittent bictegravir/emtricitabine/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV. J Pers Med, 2023; 13(4):583; doi: 10.3390/jpm13040583
18.
PalichR, SalibaS, LandowskiS, et al.Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV. Infect Dis Now, 2023:104736 [Online ahead of print]; doi: 10.1016/j.idnow.2023.104736
19.
Lambert-NiclotS, AbdiB, BelletJ, et al.Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): Substudies of reservoirs and ultrasensitive drug resistance. J Antimicrob Chemother, 2023; 78:1510–1521; doi.org/10.1093/jac/dkad119
20.
LanzafameM, DelamaA, FaitD, ColliniL, VentoS.HIV-1 RNA levels in semen of people on ‘short-cycle’ antiretroviral therapy. J Antimicrob Chemother, 2023:dkad197 [Online ahead of print]; doi: 10.1093/jac/dkad197
21.
LimaVD, BangsbergDR, HarriganPR, et al.Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr, 2010; 55(4):460–465; doi: 10.1097/QAI.0b013e3181f2ac87
22.
Groupe d'experts VIH—Optimisation d'un traitement antirétroviral en situation de succès virologique (juillet 2017). Available from: https://cns.sante.fr/wp-content/uploads/2017/01/experts-vih_optimisation.pdf [Last accessed: June 30, 2023].
23.
ReynoldsSJ, KityoC, HallahanCW, et al.A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One, 2010; 5(4):e10307; doi: 10.1371/journal.pone.0010307
